Investment Analysts’ Weekly Ratings Changes for Y-mAbs Therapeutics (YMAB)

Y-mAbs Therapeutics (NASDAQ: YMAB) recently received a number of ratings updates from brokerages and research firms:

• 8/16/2024 – Y-mAbs Therapeutics is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $20.00 price target on the stock.
• 8/13/2024 – Y-mAbs Therapeutics had its price target lowered by analysts at Morgan Stanley from $12.00 to $11.00. They now have an “underweight” rating on the stock.
• 8/13/2024 – Y-mAbs Therapeutics was upgraded by analysts at Canaccord Genuity Group Inc. to a “strong-buy” rating.
• 8/13/2024 – Y-mAbs Therapeutics had its price target lowered by analysts at BMO Capital Markets from $26.00 to $25.00. They now have an “outperform” rating on the stock.
• 8/13/2024 – Y-mAbs Therapeutics had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $26.00 price target on the stock.
• 8/13/2024 – Y-mAbs Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
• 8/12/2024 – Y-mAbs Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $23.00 price target on the stock.

Y-mAbs Therapeutics Stock Performance

Y-mAbs Therapeutics stock opened at $15.17 on Wednesday. Y-mAbs Therapeutics, Inc. has a 1 year low of $4.69 and a 1 year high of $20.90. The firm has a 50 day moving average price of $12.12 and a 200 day moving average price of $13.74. The company has a market cap of $665.71 million, a price-to-earnings ratio of -30.96 and a beta of 0.66.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The firm had revenue of $22.80 million during the quarter, compared to analyst estimates of $23.09 million. During the same period in the prior year, the firm earned ($0.14) earnings per share. Sell-side analysts predict that Y-mAbs Therapeutics, Inc. will post -0.57 EPS for the current year.

Insider Activity

In related news, insider Thomas Gad sold 35,000 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $12.03, for a total transaction of $421,050.00. Following the completion of the sale, the insider now directly owns 197,681 shares of the company’s stock, valued at approximately $2,378,102.43. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 35,000 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $12.03, for a total value of $421,050.00. Following the completion of the transaction, the insider now owns 197,681 shares in the company, valued at approximately $2,378,102.43. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,093 shares of company stock valued at $881,812. Company insiders own 21.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

Several large investors have recently modified their holdings of the business. Campbell & CO Investment Adviser LLC purchased a new position in Y-mAbs Therapeutics in the fourth quarter valued at about $562,000. Federated Hermes Inc. boosted its stake in shares of Y-mAbs Therapeutics by 4,708.0% during the 4th quarter. Federated Hermes Inc. now owns 44,474 shares of the company’s stock valued at $303,000 after buying an additional 43,549 shares during the last quarter. Sapient Capital LLC acquired a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth approximately $298,000. Bailard Inc. bought a new stake in shares of Y-mAbs Therapeutics in the fourth quarter worth $115,000. Finally, Ameritas Investment Partners Inc. raised its holdings in Y-mAbs Therapeutics by 39.9% in the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after acquiring an additional 1,056 shares in the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.